Impact of interferences including metabolite crossreactivity on therapeutic drug monitoring results

Therapeutic Drug Monitoring

Volumn 34, Issue 5, 2012, Pages 496-506

  Dasgupta, Amitava ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

active metabolite; immunoassay; interference; toxicity

Indexed keywords

CANRENOATE POTASSIUM; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CETIRIZINE; CYCLOBENZAPRINE; CYPROHEPTADINE; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; DIPHENHYDRAMINE; HETEROPHILE ANTIBODY; HYDROXYZINE; IMMUNOSUPPRESSIVE AGENT; PHENOTHIAZINE; QUETIAPINE; SPIRONOLACTONE; TRICYCLIC ANTIDEPRESSANT AGENT;

CHINESE MEDICINE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DRUG MONITORING; DRUG OVERDOSE; HUMAN; IMMUNOASSAY; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; OLEANDER APHID; PRIORITY JOURNAL;

ANIMALS; CROSS REACTIONS; DIGOXIN; DRUG MONITORING; HUMANS; IMMUNOASSAY; REPRODUCIBILITY OF RESULTS;

EID: 84866553788     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318261c2c9     Document Type: Conference Paper

References (75)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
2. Slaughter RL, Cappelletty DM. Economic impact of aminoglycoside toxicty and its prevention through therapeutic drug monitoring. Pharmacoeconomics. 1998;14:385-394.
3. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int JAntimicrob Agents. 2010;36:332-339.
4. Steimer W, Muller C, Eber B, et al. Intoxication due to negative canrenone interference in digoxin drug monitoring [letter]. Lancet. 1999;354:1176-1177.
5. Gruber KA, Whitaker JM, Buckalew VM. Endogenous digitalis-like substances in plasma of volume expanded dogs. Nature. 1980;287:743-745.
6. Craver JL, Valdes R. Anomalous serum digoxin concentration in uremia. Ann Intern Med. 1983;98:483-484.
7. Jortani SA, Valdes R Jr. Digoxin and its related endogenous factors. Crit Rev Clin Lab Sci. 1997;34:225-274.
8. Dasgupta A, Trejo O. Suppression of total digoxin concentration by digoxin-like immunoreactive substances in the MEIA digoxin assay: elimination of interference by monitoring free digoxin concentrations. Am J Clin Pathol. 1999;111:406-410.
9. Jones TE, Morris RG. Discordant results from "real-world" patient samples assayed for digoxin. Ann Pharmacother. 2008;42:1797-1803.
10. Rainey P. Digibind and free digoxin [letter]. Clin Chem. 1999;45:719-720.
11. McMillin GA, Qwen W, Lambert TL, et al. Comparable effects of DIG-IBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem. 2002; 48:1580-1584.
12. Morris RG, Frewin DB, Taylor WB, et al. The effect of renal and hepatic impairment and of spironolactone on serum digoxin assay. Eur J Clin Pharmacol. 1988;34:233-239.
13. Okazaki M, Tanigawara Y, Kita T, et al. Cross-reactivity of TDX and OPUS immunoassay system for serum digoxin determination. Ther Drug Monit. 1997;19:657-662.
14. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem. 2002;48:507-516.
15. Howard G, Barclay M, Florkowski C, et al. Lack of clinically significant interference by spironolactone with the AxSYM digoxin II assay. Ther Drug Monit. 2003;25:112-113.
16. Steimer W. Lack of critically significant interference by spironolactone with the AxSYM digoxin II assay only applies to low dose therapy with spironolactone [letter]. Ther Drug Monit. 2003;25:484-485.
17. DeFrance A, Armbruster D, Petty D, et al. Abbott ARCHITECT clinical chemistry and immunoassay systems-digoxin assays are free of interferences from spironolactone, potassium canrenoate and their common metabolite canrenone. Ther Drug Monit. 2011;33:128-131.
18. Liendo C, Ghali JK, Graves SW. A new interference in some digoxin assays: anti-murine heterophilic antibodies. Clin Pharmacol Ther. 1996;60:593-598.
19. Chow L, Johnson M, Wells A, et al. Effect of the traditional Chinese medicine Chan Su, Lu-Shen-Wan, DanShen and Asian ginseng on serum digoxin measurement by Tina-Quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal. 2003;17:22-27.
20. Eddleston M, Ariaratnam CA, Sjostrom L, et al. Acute yellow oleander (Thevetia peruvica) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital. Heart. 2000;83:301-306.
21. Dasgupta A, Datta P. Rapid detection of oleander poisoning by using digoxin immunoassays: comparison of five assays. Ther Drug Monit. 2004;26:658-663.
22. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ. 1996;155:293-295.
23. Potter JM, Donnelly A. Carbamazepine 10, 11-epoxide in therapeutic drug monitoring. Ther Drug Monit. 1998;20:652-657.
24. Tutor-Crespo MJ, Hermida J, Tutor JC. Relative proportions of serum carbamazepine and its pharmacologically active 10, 11-epoxide derivative: effect of polytherapy and renal insufficiency. Ups J Med Sci. 2008; 113:171-180.
25. Hermida J, Tutor JC. How suitable are currently used carbamazepine immunoassays for quantifying Carbamazepine 10, 11-epoxide in serum samples? Ther Drug Monit. 2003;25:384-388.
26. Parant F, Bossu H, Gagnieu MC, et al. Cross reactivity assessment of carbamazepine 10, 11-epoxide, oxcarbazepine, and 10 hydroxy carbama-zepine in two automated carbamazepine immunoassay: PENTINA and EMIT 2000. Ther Drug Monit. 2003;25:41-45.
27. Rambert B, Salke-Treumann A, May T, et al. Valproic acid induced carbamzepine 10, 11-epoxide toxicity in children and adolescents. Eur Neurol. 1990;30:79-83.
28. Fitzerald BJ, Okos AJ. Elevation of carbamazepine 10, 11-epoxide by quetiapine. Pharmacotherapy. 2002;22:1500-1503.
29. McMillin GA, Juenke JM, Tso G, et al. Estimation of carbamazepine and carbamazepine 10, 11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays. Am J Clin Pathol. 2010;133:728-736.
30. Pankey DC, Collins A, Jaklitsch A, et al. Quantitative homogeneous enzyme immunoassays for amitriptyline, nortriptyline, imipramine, and desipramine. Clin Chem. 1986;32:768-772.
31. Poklis A, Soghoian D, Crooks CR, et al. Evaluation of the Abbott ADX total serum tricyclic immunoassay. J Toxicol Clin Toxicol. 1990;28:235-248.
32. Hackett LP, Dusci LJ, IIett KF. A comparison of high-performance liquid chromatography and fluorescence polarization immunoassay for therapeutic drug monitoring of tricyclic antidepressants. Ther Drug Monit. 1998;20:30-34.
33. Schroeder TJ, Tasset JJ, Otten EJ, et al. Evaluation of Syva EMIT toxicolog-ical serum tricyclic antidepressant assay. J Anal Toxicol. 1986;10:221-224.
34. Ryder KW, Glick MR. The effect of thioridazine on the automatic clinical analyzer serum tricyclic anti-depressant screen. Am J Clin Pathol. 1986;86:248-249.
35. Dasgupta A, McNeese C, Wells A. Interference of carbamazepine and carbamazepine 10, 11-epoxide in the fluorescence polarization immunoassay for tricyclic antidepressants: estimation of the true tricyclic antidepressant concentration in the presence of carbamazepine using a mathematical model. Am J Clin Pathol. 2003;121:418-425.
36. Chattergoon DS, Verjee Z, Anderson M, et al. Carbamazepine interference with an immunoassay for tricyclic antidepressant. J Toxicol Clin Toxicol. 1998;36:109-113.
37. Wians FH Jr, Norton JT, Wirebaugh SR. False-positive serum tricyclic antidepressant screen with cyproheptadine. Clin Chem. 1993;39:1355-1356.
38. Sloan KL, Haver VM, Saxon AJ. Quetiapine and false-positive urine drug testing for tricyclic antidepressants. Am J Psychiatry. 2000;157:148-149.[Letter to the editor].
39. Cerullo MA, Albertz AA, Bell JN, et al. Tricyclic antidepressant immunoassays may reflect quetiapine adherence. Am J Psychiatry. 2008;165:919-920 [Letter to the editor].
40. Dasgupta A, Wells A, Datta P. False positive serum tricyclic antidepressant concentrations using fluorescence polarization immunoassay due to the presence of hydroxyzine and cetirizine. Ther Drug Monit. 2007;29:134-139.
41. Sorisky A, Watson DC. Positive diphenhydramine interference in the EMIT-st assay for tricyclic antidepressants in serum Clin Chem. 1986;32:715.
42. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem. 1999; 45:371-381.
43. Schutz E, Svinarov D, Shipkova M, et al. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem. 1998; 44:2158-2164.
44. Hamwi A, Veitl M, Manner G, et al. Evaluation of four automated methods for determination of whole blood cyclosporine concentrations. Am J Clin Pathol. 1999;112:358-365.
45. Terrell AR, Daly TM, Hock KG, et al. Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring Dimension RxL clinical analyzer. Clin Chem. 2002;48:1059-1065.
46. Butch AW, Fukuchi AM. Analytical performance of the CEDIA® cyclosporine PLUS whole blood immunoassay. J Anal Toxicol. 2004;28:204-210.
47. Wallemacq P, Maine GT, Berg K, et al. Multisite analytical evaluation of Abbott Architect cyclosporine assay. Ther Drug Monit. 2010;32:145-151.
48. Soldin SJ, Hardy RW, Wians FH, et al. Performance evaluation of the new ADVIA Centaur system cyclosporine assay (single-step extraction). Clin Chim Acta. 2010;411:806-811.
49. Westley IS, Taylor PJ, Salm P, et al. Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatogra-phy-tandem mass spectrometry in liver and renal transplant recipients. Ther Drug Monit. 2007;29:584-591.
50. Bazin C, Guinedor A, Barau C, et al. Evaluation of the architect tacrolimus assay in kidney, liver and heart transplant recipients. J Pharm Biomed Appl. 2010;53:997-1002.
51. Colantonio DA, Borden KK, Clarke W. Comparison of the CEDIA and MEIA assays for the measurement of sirolimus in organ transplant recipients. Clin Biochem. 2007;40:680-687.
52. Morris RG, Salm P, Taylor PJ, et al. Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole blood sirolimus from transplant recipients. Ther Drug Monit. 2006;28:164-168.
53. Schmidt RW, Lotz J, Schweigert R, et al. Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer. Clin Biochem. 2009;42:1543-1548.
54. Dasgupta A, Davis B, Chow L. Evaluation of QMS everolimus assay using Hitachi 917 analyzer: comparison with liquid chromatography/mass spectrometry. Ther Drug Monit. 2011;33:149-154.
55. Sallustio BC, Noll BD, Morris RG. Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLC-UV and immunoassay methods. Clin Biochem. 2011;44:231-236.
56. Hosotsubo H, Takahara S, Imamura R, et al. Analytical validation of the enzyme multiplied immunoassay technique for the determination of my-cophenolic acid in plasma from renal transplant recipients compared with a high performance liquid chromatographic assay. Ther Drug Monit. 2001;23:669-674.
57. Westley IS, Ray JE, Morris RG. CEDIA mycophenolic acid assay compared with HPLC-UV in specimens from transplant recipients. Ther Drug Monit. 2006;28:632-636.
58. De Jonge H, Geerts I, Declercq P, et al. Apparent elevation of cyclospor-ine whole blood concentration in a renal allograft recipient. Ther Drug Monit. 2010;32:529-531.
59. Barcelo-Martin B, Marquet P, Ferrer JM, et al. Rheumatoid factor interference in a tacrolimus immunoassay. Ther Drug Monit. 2009;31:743-745.
60. Altinier S, Varagnolo M, Zaninotto M, et al. Heterophilic antibody interference in a non-endogenous molecule assay: an apparent elevation in the tacrolimus concentration. Clin Chim Acta. 2009;402:193-195.
61. Armedariz Y, Garcia S, Lopez R, et al. Hematocrit influences immuno-assay performance for the measurement of tacrolimus in whole blood. Ther Drug Monit. 2005;27:766-769.
62. Frank EL, Schwarz EL, Juenke J, et al. Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol. 2002;118:124-131.
63. Datta P, Dasgupta A. Cross-reactivity of fosphenytoin in four phenytoin immunoassays. Clin Chem. 1998;44:696-697.
64. Kugler AR, Annesley TM, Nordblom GD, et al. Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays. Clin Chem. 1998;44:1474-1480.
65. Roberts WL, De BK, Coleman JP, et al. Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem. 1999;45:829-837.
66. Dasgupta A, Warner B, Datta P. Use of alkaline phosphatase to correct underestimation of fosphenytoin concentrations in serum measured by phenytoin immunoassays. Am J Clin Pathol. 1999;111:557-562.
67. Annesley T, Kurzyniec S, Nordblom G, et al. Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin. Clin Chem. 2001:46:910-918.
68. Parant F, Moulsma M, Gagnieu MC, et al. Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidi-metric inhibition immunoassay (PETINIA). Ther Drug Monit. 2005;27:457-462.
69. Dasgupta A, Tso G, Johnson M, et al. Hydroxyzine and cetirizine interfere with the PETINIA carbamazepine assay but not with the ADVIA CENTEUR carbamazepine assay. Ther Drug Monit. 2010;32:112-115.
70. Matuszewski BK, Constanzer MI, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030.
71. Vethe NT, Gjerdalen LC, Bergan S. Determination of cyclosporine, tacroli-mus, sirolimus, and everolimus by liquid chromatography coupled to electro-spray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance. Scand J Clin Lab Invest. 2010;70:583-591.
72. Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003; 49:1041-1044.
73. Yan Z, Maher N, Torres R, et al. Isobaric metabolite interferences and the requirement for the close examination of raw data in addition to stringent chromatographic separations in liquid chromatography/tandem mass spectrometric analysis of drugs in biological matrix. Rapid Commun Mass Spectrom. 2008;22:2012-2028.
74. Vogeser M, Spohrer U. Pitfall in the high throughput quantification of whole blood cyclosporine A using liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med. 2005;43:400-402.
75. Vogeser M, Zachoval R, Spoherr U, et al. Potential lack of specificity using electrospray tandem-mass spectrometry for the analysis of myco-phenolic acid in serum. Ther Drug Monit. 2001;23:722-724.